Background and Need for Legislation
This legislation reauthorizes the National Breast and
Cervical Cancer Early Detection Program (NBCCEDP) that provides
access to breast cancer screening and diagnostic services for
low-income, uninsured, or underinsured people in all 50 states,
the District of Columbia, two U.S. territories, five U.S.-
affiliated Pacific Islands and 13 tribes or tribal
organizations. The legislation updates the program to improve
the ability for women to access breast and cervical cancer
screening services. The NCCEDP also provides public education,
outreach, patient navigation, and care coordination services to
increase breast and cervical cancer screening rates and reach
underserved populations. For women aged 50 to 74 years old,
breast cancer screening every 2 years reduces breast cancer
deaths by 26 percent, or 7 deaths averted for every 1,000 women
screened.\1\ When diagnosed at the earliest stage, almost 98
percent of women diagnosed with breast cancer live for 5 years
or more, compared to about 31 percent of those diagnosed at the
most advanced stage.\2\
---------------------------------------------------------------------------
\1\Centers for Disease Control and Prevention, ``Health and
Economic Benefits of Breast Cancer Interventions'', National Center for
Chronic Disease Prevention and Health Promotion (NCCDPHP), 2022.
https://www.cdc.gov/chronicdisease/programs-impact/pop/breast-
cancer.htm.
\2\Id.
---------------------------------------------------------------------------
Committee Action
On February 14, 2024, the Subcommittee on Health held a
hearing on H.R. 3916. The title of the hearing was
``Legislative Proposals to Support Patients and Caregivers.''
The Subcommittee received testimony from:
Andy Shih, PhD, Chief Science Officer,
Autism Speaks;
Corey Feist, JD, MBA, Co-Founder and CEO,
Dr. Lorna Breen Heroes' Foundation;
Joanne Pike, DrPH, President and CEO,
Alzheimer's Association;
Gordon Tomaselli, MD, Former President,
American Heart Association; Marilyn and Stanley M. Katz
Dean, Emeritus and Professor of Medicine, Albert
Einstein College of Medicine; Adjunct Professor of
Medicine, Johns Hopkins University School of Medicine;
Michelle Whitten, President, CEO, and Co-
Founder, Global Down Syndrome Foundation;
Randy Strozyk, President, American Ambulance
Association; and
Christina Annunziata, MD, PhD, Senior Vice
President of Extramural Discovery Science, American
Cancer Society.
On March 12, 2024, the Subcommittee on Health met in open
markup session and forwarded H.R. 3916, as amended, to the full
Committee by a record vote of 24 yeas and 0 nays.
On March 20, 2024, the full Committee on Energy and
Commerce met in open markup session and ordered H.R. 3916, as
amended, favorably reported to the House by a record vote of 46
yeas and 0 nays.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to improve
the ability for communities to detect breast cancer and
cervical cancer at early stages.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 3916 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearing was used to develop or consider H.R. 3916:
On February 14, 2024, the Subcommittee on
Health held a hearing on H.R. 3916. The title of the
hearing was ``Legislative Proposals to Support Patients
and Caregivers.'' The Subcommittee received testimony
from:
Andy Shih, PhD, Chief Science
Officer, Autism Speaks;
Corey Feist, JD, MBA, Co-Founder
and CEO, Dr. Lorna Breen Heroes' Foundation;
Joanne Pike, DrPH, President and
CEO, Alzheimer's Association;
Gordon Tomaselli, MD, Former
President, American Heart Association; Marilyn
and Stanley M. Katz Dean, Emeritus and
Professor of Medicine, Albert Einstein College
of Medicine; Adjunct Professor of Medicine,
Johns Hopkins University School of Medicine;
Michelle Whitten, President,
CEO, and Co-Founder, Global Down Syndrome
Foundation;
Randy Strozyk, President,
American Ambulance Association; and
Christina Annunziata, MD, PhD,
Senior Vice President of Extramural Discovery
Science, American Cancer Society.
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 3916 contains no earmarks, limited
tax benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 provides that the Act may be cited as the
``Screening for Communities to Receive Early and Equitable
Needed Services for Cancer Act of 2024'' or the ``SCREENS for
Cancer Act of 2024''.
Section 2. National breast and cervical cancer early detection
program
Section 2 amends Title XV of the Public Health Service Act
to reauthorize the National Breast and Cervical Cancer Early
Detection Program through fiscal year 2029. This section also
makes updates to the program to reduce disparities and support
certain activities that improve cancer screening rates.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
PUBLIC HEALTH SERVICE ACT
* * * * * * *
TITLE XV--PREVENTIVE HEALTH MEASURES WITH RESPECT TO
BREAST AND CERVICAL CANCERS
SEC. 1501. ESTABLISHMENT OF PROGRAM OF GRANTS TO STATES.
(a) In General.--The Secretary, acting through the Director
of the Centers for Disease Control and Prevention, may make
grants to States on the basis of an established competitive
review process for the purpose of carrying out programs--
(1) to screen women for breast and cervical cancer as
a preventive health measure;
(2) to provide appropriate referrals for medical
treatment of women screened pursuant to paragraph (1)
and to ensure, to the extent practicable, [the
provision of appropriate follow-up services and support
services such as case management] that appropriate
follow-up services are provided;
(3) to develop and disseminate public information and
education [programs for the detection and control] for
the prevention, detection, and control of breast and
cervical cancer;
(4) to improve the education, training, and skills of
health professionals (including allied health
professionals) in [the detection and control] the
prevention, detection, and control of breast and
cervical cancer;
(5) to establish mechanisms through which the States
can [monitor] ensure the quality of screening
procedures for breast and cervical cancer, including
the interpretation of such procedures[; and];
(6) to enhance appropriate support activities to
increase breast and cervical cancer screening, such
as--
(A) patient navigation;
(B) implementation of evidence-based or
evidence-informed strategies proven to increase
breast and cervical cancer screening in health
care settings; and
(C) facilitating access to health care
settings that provide breast and cervical
cancer screenings;
(7) to reduce disparities in incidents of and deaths
due to breast and cervical cancer in populations with
higher than average rates;
(8) to improve access to breast and cervical cancer
screening and diagnostic services and reduce related
barriers, including factors that relate to negative
health outcomes; and
[(6)] (9) to evaluate activities conducted under
paragraphs (1) [through (5)] through (8) through
appropriate surveillance or program-monitoring
activities.
(b) Grant and Contract Authority of States.--
(1) In general.--A State receiving a grant under
subsection (a) may, subject to paragraphs (2) and (3),
expend the grant to carry out the purpose described in
such subsection through grants to public and nonprofit
private entities and through contracts with public and
private entities.
(2) Certain applications.--If a nonprofit private
entity and a private entity that is not a nonprofit
entity both submit applications to a State to receive
an award of a grant or contract pursuant to paragraph
(1), the State may give priority to the application
submitted by the nonprofit private entity in any case
in which the State determines that the quality of such
application is equivalent to the quality of the
application submitted by the other private entity.
(3) Payments for screenings.--The amount paid by a
State to an entity under this subsection for a
screening procedure under subsection (a)(1) may not
exceed the amount that would be paid under part B of
title XVIII of the Social Security Act if payment were
made under such part for furnishing the procedure to a
woman enrolled under such part.
(c) Special Consideration for Certain States.--In making
grants under subsection (a) to States whose initial grants
under such subsection are made for fiscal year 1995 or any
subsequent fiscal year, the Secretary shall give special
consideration to any State whose proposal for carrying out
programs under such subsection--
(1) has been approved through a process of peer
review; and
(2) is made with respect to geographic areas in which
there is--
(A) a substantial rate of mortality from
breast or cervical cancer; or
(B) a substantial incidence of either of such
cancers.
[(d) Coordinating Committee Regarding Year 2020 Health
Objectives.--The Secretary, acting through the Director of the
Centers for Disease Control and Prevention, shall establish a
committee to coordinate the activities of the agencies of the
Public Health Service (and other appropriate Federal agencies)
that are carried out toward achieving the objectives
established by the Secretary for reductions in the rate of
mortality from breast and cervical cancer in the United States
by the year 2020. Such committee shall be comprised of Federal
officers or employees designated by the heads of the agencies
involved to serve on the committee as representatives of the
agencies, and such representatives from other public or private
entities as the Secretary determines to be appropriate.]
* * * * * * *
SEC. 1503. REQUIREMENTS WITH RESPECT TO TYPE AND QUALITY OF
SERVICES.
(a) Requirement of Provision of All Services by Date
Certain.--The Secretary may not make a grant under section 1501
unless the State involved agrees--
(1) to ensure [that, initially and throughout the
period during which amounts are received pursuant to
the grant, not less than 60 percent of the grant is
expended to provide each of the services or activities
described in paragraphs (1) and (2) of section 1501(a),
including making available screening procedures for
both breast and cervical cancers;] that appropriate
breast and cervical cancer screening and diagnostic
services are provided based on national
recommendations; and
[(2) subject to subsection (b), to ensure that--
[(A) in the case of breast cancer, both a
physical examination of the breasts and the
screening procedure known as a mammography are
conducted; and
[(B) in the case of cervical cancer, both a
pelvic examination and the screening procedure
known as a pap smear are conducted;]
[(3)] (2) to ensure that, by the end of any second
fiscal year of payments pursuant to the grant, each of
the services or activities described in section 1501(a)
is provided[; and].
[(4) to ensure that not more than 40 percent of the
grant is expended to provide the services or activities
described in paragraphs (3) through (6) of such
section.]
(b) Use of Improved Screening Procedures.--The Secretary may
not make a grant under section 1501 unless the State involved
agrees that, if any screening procedure superior to a procedure
described in subsection (a)(2) becomes commonly available and
is recommended for use, any entity providing screening
procedures pursuant to the grant will utilize the superior
procedure rather than the procedure described in such
subsection.
(c) Quality Assurance Regarding Screening Procedures.--The
Secretary may not make a grant under section 1501 unless the
State involved agrees that the State will, in accordance with
applicable law, assure the quality of screening procedures
conducted pursuant to such section.
[(d) Waiver of Services Requirement on Division of Funds.--
[(1) In general.--The Secretary shall establish a
demonstration project under which the Secretary may
waive the requirements of paragraphs (1) and (4) of
subsection (a) for not more than 5 States, if--
[(A) the State involved will use the waiver
to leverage non-Federal funds to supplement
each of the services or activities described in
paragraphs (1) and (2) of section 1501(a);
[(B) the application of such requirement
would result in a barrier to the enrollment of
qualifying women;
[(C) the State involved--
[(i) demonstrates, to the
satisfaction of the Secretary, the
manner in which the State will use such
waiver to expand the level of screening
and follow-up services provided
immediately prior to the date on which
the waiver is granted; and
[(ii) provides assurances,
satisfactory to the Secretary, that the
State will, on an annual basis,
demonstrate, through such documentation
as the Secretary may require, that the
State has used such waiver as described
in clause (i);
[(D) the State involved submits to the
Secretary--
[(i) assurances, satisfactory to the
Secretary, that the State will maintain
the average annual level of State
fiscal year expenditures for the
services and activities described in
paragraphs (1) and (2) of section
1501(a) for the period for which the
waiver is granted, and for the period
for which any extension of such wavier
is granted, at a level that is not less
than--
[(I) the level of the State
fiscal year expenditures for
such services and activities
for the fiscal year preceding
the first fiscal year for which
the waiver is granted; or
[(II) at the option of the
State and upon approval by the
Secretary, the average level of
the State expenditures for such
services and activities for the
3-fiscal year period preceding
the first fiscal year for which
the waiver is granted; and
[(ii) a plan, satisfactory to the
Secretary, for maintaining the level of
activities carried out under the waiver
after the expiration of the waiver and
any extension of such waiver;
[(E) the Secretary finds that granting such a
waiver to a State will increase the number of
women in the State that receive each of the
services or activities described in paragraphs
(1) and (2) of section 1501(a), including
making available screening procedures for both
breast and cervical cancers; and
[(F) the Secretary finds that granting such a
waiver to a State will not adversely affect the
quality of each of the services or activities
described in paragraphs (1) and (2) of section
1501(a).
[(2) Duration of waiver.--
[(A) In general.--In granting waivers under
paragraph (1), the Secretary--
[(i) shall grant such waivers for a
period that is not less than 1 year but
not more than 2 years; and
[(ii) upon request of a State, may
extend a waiver for an additional
period that is not less than 1 year but
not more than 2 years in accordance
with subparagraph (B).
[(B) Additional period.--The Secretary, upon
the request of a State that has received a
waiver under paragraph (1), shall, at the end
of the waiver period described in subparagraph
(A)(i), review performance under the waiver and
may extend the waiver for an additional period
if the Secretary determines that--
[(i) without an extension of the
waiver, there will be a barrier to the
enrollment of qualifying women;
[(ii) the State requesting such
extended waiver will use the waiver to
leverage non-Federal funds to
supplement the services or activities
described in paragraphs (1) and (2) of
section 1501(a);
[(iii) the waiver has increased, and
will continue to increase, the number
of women in the State that receive the
services or activities described in
paragraphs (1) and (2) of section
1501(a);
[(iv) the waiver has not, and will
not, result in lower quality in the
State of the services or activities
described in paragraphs (1) and (2) of
section 1501(a); and
[(v) the State has maintained the
average annual level of State fiscal
expenditures for the services and
activities described in paragraphs (1)
and (2) of section 1501(a) for the
period for which the waiver was granted
at a level that is not less than--
[(I) the level of the State
fiscal year expenditures for
such services and activities
for the fiscal year preced